These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9646891)

  • 1. Nicotinic receptor desensitization and sensory gating deficits in schizophrenia.
    Griffith JM; O'Neill JE; Petty F; Garver D; Young D; Freedman R
    Biol Psychiatry; 1998 Jul; 44(2):98-106. PubMed ID: 9646891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics.
    Adler LE; Hoffer LJ; Griffith J; Waldo MC; Freedman R
    Biol Psychiatry; 1992 Oct; 32(7):607-16. PubMed ID: 1450287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia.
    Potter D; Summerfelt A; Gold J; Buchanan RW
    Schizophr Bull; 2006 Oct; 32(4):692-700. PubMed ID: 16469942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P50 amplitude reduction: a nicotinic receptor-mediated deficit in first-degree relatives of schizophrenia patients.
    Turetsky BI; Dent G; Jaeger J; Zukin SR
    Psychopharmacology (Berl); 2012 May; 221(1):39-52. PubMed ID: 22048129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normalization of the auditory P50 gating deficit of schizophrenic patients after non-REM but not REM sleep.
    Griffith JM; Freedman R
    Psychiatry Res; 1995 Apr; 56(3):271-8. PubMed ID: 7568549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tropisetron improves deficits in auditory P50 suppression in schizophrenia.
    Koike K; Hashimoto K; Takai N; Shimizu E; Komatsu N; Watanabe H; Nakazato M; Okamura N; Stevens KE; Freedman R; Iyo M
    Schizophr Res; 2005 Jul; 76(1):67-72. PubMed ID: 15927799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normalization of auditory sensory gating in schizophrenic patients after a brief period for sleep.
    Griffith JM; Waldo M; Adler LE; Freedman R
    Psychiatry Res; 1993 Oct; 49(1):29-39. PubMed ID: 8140180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nicotinic cholinergic normalization of amphetamine-induced loss of auditory gating in freely moving rats.
    Stevens KE; Meltzer J; Rose GM
    Psychopharmacology (Berl); 1995 May; 119(2):163-70. PubMed ID: 7659763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of nicotine on the amplitude and gating of the auditory P50 and its influence by dopamine D2 receptor gene polymorphism.
    Knott V; Millar A; Fisher D; Albert P
    Neuroscience; 2010 Mar; 166(1):145-56. PubMed ID: 19961902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline dependency of nicotine's sensory gating actions: similarities and differences in low, medium and high P50 suppressors.
    Knott V; de la Salle S; Smith D; Phillipe T; Dort H; Choueiry J; Impey D
    J Psychopharmacol; 2013 Sep; 27(9):790-800. PubMed ID: 23744798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
    Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
    Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schizophrenia, sensory gating, and nicotinic receptors.
    Adler LE; Olincy A; Waldo M; Harris JG; Griffith J; Stevens K; Flach K; Nagamoto H; Bickford P; Leonard S; Freedman R
    Schizophr Bull; 1998; 24(2):189-202. PubMed ID: 9613620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic modulation of the P50 auditory-evoked potential in a computer model of the CA3 region of the hippocampus: its relationship to sensory gating in schizophrenia.
    Moxon KA; Gerhardt GA; Adler LE
    Biol Cybern; 2003 Apr; 88(4):265-75. PubMed ID: 12690485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.
    Martin LF; Kem WR; Freedman R
    Psychopharmacology (Berl); 2004 Jun; 174(1):54-64. PubMed ID: 15205879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia.
    Zhang XY; Liu L; Liu S; Hong X; Chen DC; Xiu MH; Yang FD; Zhang Z; Zhang X; Kosten TA; Kosten TR
    Am J Psychiatry; 2012 Sep; 169(9):974-81. PubMed ID: 22952075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder.
    Cadenhead KS; Light GA; Geyer MA; Braff DL
    Am J Psychiatry; 2000 Jan; 157(1):55-9. PubMed ID: 10618013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers.
    Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
    J Psychopharmacol; 2019 Jun; 33(6):688-699. PubMed ID: 30920339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicotinic receptor function in schizophrenia.
    Leonard S; Adams C; Breese CR; Adler LE; Bickford P; Byerley W; Coon H; Griffith JM; Miller C; Myles-Worsley M; Nagamoto HT; Rollins Y; Stevens KE; Waldo M; Freedman R
    Schizophr Bull; 1996; 22(3):431-45. PubMed ID: 8873294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved p50 auditory gating with ondansetron in medicated schizophrenia patients.
    Adler LE; Cawthra EM; Donovan KA; Harris JG; Nagamoto HT; Olincy A; Waldo MC
    Am J Psychiatry; 2005 Feb; 162(2):386-8. PubMed ID: 15677607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicotinic modulation of auditory evoked potential electroencephalography in a rodent neurodevelopmental model of schizophrenia.
    Kohlhaas KL; Robb HM; Roderwald VA; Rueter LE
    Biochem Pharmacol; 2015 Oct; 97(4):482-487. PubMed ID: 26032639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.